


7/1/2025 Provider Biosimilars eToolkit

• Effective July 1, 2025, Optum Rx will implement a new formulary strategy which excludes Humira and Stelara from commercial and exchange formularies and presents biosimilars as the preferred alternatives.


Optum Rx offers providers additional support to help guide patients through these coverage changes.

MATERIALS ARE READY FOR DOWNLOADING:



Provider Biosimilars FAQs

Answers key questions providers may have regarding upcoming formulary changes.




Biosimilars 'Cheat Sheet'

Provides an 'at-a-glance' guide to the Optum Rx 7/1/2025 biosimilars strategy for both Humira and Stelara.



Biosimilars Support Article

Provides additional information about the change, including notification strategy and timing.



Notification Examples

Includes copies of both patient and provider notifications regarding these updates.

Provider Notification
Patient Notification



Optum

^{*} Optum Rx also supports clients with custom formulary strategies which may deviate from our standard patient coverage approach. Please remember to verify patient coverage before you submit or renew a prescription.